Oncostatin M/OSM Antibody (17022)

Human monocyte-derived dendritic cells were stained with Mouse Anti-Human Oncostatin M Monoclonal Antibody (Catalog # MAB2951, filled histogram) or isotype control antibody (Catalog # MAB003, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin.

Recombinant Human Oncostatin M (Catalog # 295‑OM) stimulates proliferation in the TF‑1 human erythro­leukemic cell line in a dose-dependent manner (orange line). Prolif­eration elicited by Recom­binant Human Oncostatin M (2 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Oncostatin M Monoclonal Antibody (Catalog # MAB2951). The ND50 is typically 0.3‑1.5 µg/mL.

• Reactivity: Hu
• Applications: B/N, CyTOF-ready, Flow
• Clone: 17022
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Oncostatin M/OSM Antibody (17022) Summary

• Immunogen: E. coli-derived recombinant human Oncostatin M/OSM
  Ala26-Arg221
  Accession # P13725
• Specificity: Detects human Oncostatin M/OSM in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse Oncostatin M, recombinant human (rh) CLC, rhCNTF, rhCardiotrophin-1, rhIL-6, rhIL-11, or rhLIF is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: OSM
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Intracellular Staining by Flow Cytometry 2.5 ug/10^6 cells
  • Neutralization 0.3-1.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.5 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Oncostatin M/OSM Antibody (17022)

• MGC20461
• oncostatin M
• oncostatin-M
• OSM

Background

Oncostatin M (OSM) is a cytokine originally isolated from medium conditioned by PMA-treated U-937 human histiocytic leukemia cells based on its ability to inhibit growth of A375 melanoma cells. The human OSM cDNA encodes a 252 amino acid pre-pro-OSM polypeptide with a 25 residue hydrophobic signal peptide and a hydrophilic C-terminal domain that are proteolytically processed to generate the 196 residue mature form of OSM. Although both mature and pro-OSM are equally active in radio-receptor assays, the mature OSM is 5- to 60-fold more active in growth inhibition assays. Thus, proteolytic processing of the pro-OSM peptide may be important in regulating the in vivo activities of OSM. OSM is a pleiotropic cytokine that initiates its biological activities by binding to specific cell surface receptors. The biological activity of human OSM is mediated either by the LIF/OSM receptor complex composed of gp130 and LIF R alpha or by a human OSM specific receptor composed of gp130 and OSM R alpha . The gp130, a signal transducing component ( beta subunit) of the IL-6, LIF and CNTF receptor complexes, was identified as a low-affinity OSM receptor that does not transduce OSM signals. The low affinity LIF receptor (LIF R, a gp130-related protein) has been identified to be a component of a high-affinity OSM receptor that will transduce OSM signals. Besides its growth inhibitory activities on human A375 melanoma and mouse M1 myeloid leukemic cells, as well as on other solid tumor cells, OSM also has growth stimulatory activities on normal fibroblasts, AIDS-Kaposi’s sarcoma cells, and a human erythroleukemia cell line, TF-1. Other OSM-mediated activities reported to date include: stimulation of plasminogen activator activity in cultured bovine aortic endothelial cells; regulation of IL-6 expression in human endothelial cells; and stimulation of LDL uptake and up-regulation of cell surface LDL receptors in HepG2 cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: OSM
• Uniprot:
  • P13725()